학술논문

Exploring the Mystery of the Tetrahydrobiopterin Synthetic Defect Lethal Mutant lem l from Birth to Death in the Silkworm Bombyx mori.
Document Type
Article
Source
International Journal of Molecular Sciences. Oct2022, Vol. 23 Issue 20, p12083-N.PAG. 15p.
Subject
*SILKWORMS
*TETRAHYDROBIOPTERIN
*NITRIC-oxide synthases
*PHOSPHOLIPASE A2
*MELANOGENESIS
*EPIDERMAL growth factor receptors
*PHOSPHOLIPASES
Language
ISSN
1661-6596
Abstract
Tetrahydrobiopterin (BH4) is a vital coenzyme for several enzymes involved in diverse enzymatic reactions in animals, and BH4 deficiency can lead to metabolic and neurological disorders due to dysfunction in its metabolism. In the silkworm natural homozygous mutant leml, the key enzyme sepiapterin reductase (BmSPR) in the de novo synthesis pathway of BH4 is inactivated, resulting in severe deficiency of BH4 synthesis. However, it is not known why the leml larvae can survive to the second-instar stage and which pathways lead to their death when BH4 is deficient. Here, we quantified BH4 and found that the fertilized eggs contained large amounts of BH4 transferred from the mother to the offspring, maintaining its normal development in the embryo and the first instar. Subsequently, we investigated the multiple pathways in which BH4 is involved as a cofactor. The results showed that BH4 deficiency in silkworms blocked the melanin synthesis pathway, caused an insufficient degree of epidermal sclerosis, disordered tyrosine metabolism, and damaged mitochondria. On the other hand, BH4 deficiency led to the uncoupling of nitric oxide synthase (BmNOS), a reduced NO production, and a significantly reduced fat in fat body catalyzation by phospholipase A2, resulting in an impaired immune system. Meanwhile, the uncoupling of BmNOS increased the O2− content, damaged the DNA, and caused the apoptosis of the body cells. Taken together, BH4 is critical for the life and death of leml mutants. This study lays a foundation for the further exploration of lepidopteran insects and provides an important basis for the treatment of human BH4 deficiency-related diseases. [ABSTRACT FROM AUTHOR]